RVL Pharmaceuticals plc (NASDAQ:RVLP) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET

Company Participants

Lisa Wilson – Investor Relations

Brian Markison – Chief Executive Officer

JD Schaub – Chief Operating Officer

Mike DePetris – Interim Chief Financial Officer

Conference Call Participants

Louise Chen – Cantor Fitzgerald

Douglas Tsao – H.C Wainwright

John Vandermosten – Zacks

Operator

Good day, everyone. My name is Chelsea, and I'll be your conference operator. At this time, I'd like to welcome everyone to the RVL Pharmaceuticals Third Quarter 2022 Financial Results Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer period. [Operator Instructions] As a reminder, this conference call is being recorded today, November 10, 2020. It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for RVL Pharmaceuticals. Please go ahead.

Lisa Wilson

Thank you, operator. Welcome to RVL Pharmaceuticals third quarter 2022 financial results and commercial update call. This is Lisa Wilson, Investor Relations for RVL. With me on today's call are RVL's Chief Executive Officer, Brian Markison; Chief Operating Officer, JD Schaub; and Interim Chief Financial Officer, Mike DePetris. This afternoon, the company issued a press release detailing financial results for the three months ended September 30, 2022. This press release and a webcast of this call can be accessed through the Investors section of the RVL website at rvlpharma.com.

Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation or intent regarding future events and the company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to management as of today and involve risks and uncertainties, including those noted in this afternoon's press release and the company's filings with the Securities and Exchange Commission. Such forward-looking statements are not guarantees of future performance.

Actual results may differ materially from those projected in the forward-looking statements. RVL specifically disclaims any intent or obligation to update these forward-looking statements, except as required by law. During this call, we refer to non-GAAP financial measures such as adjusted EBITDA. For a reconciliation of adjusted EBITDA to net income or loss from continuing operations, please see the tables at the end of today's press release. The archived webcast of this call will be available for one year on RVL's website, rvlpharm.com. For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on Thursday, November 10, 2022. Since then, RVL may have made announcements related to the topics discussed, so please reference the company's most recent press releases and SEC filings.